Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXNNASDAQ:AIMDNASDAQ:ELABNASDAQ:HCWB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$9.43+0.2%$8.27$6.51▼$13.27$9.97M1.6594,824 shs44,098 shsAIMDAinos$2.67-5.7%$0.60$2.00▼$5.35$11.86M2.1459,186 shs94,742 shsELABPMGC$2.33+7.9%$2.28$1.95▼$839.86$2.97M0.11381,837 shs250,068 shsHCWBHCW Biologics$3.75-5.3%$6.76$3.23▼$100.80$5.71M0.66280,635 shs91,932 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics+5.02%+8.47%+21.50%+27.25%+14.47%AIMDAinos+466.00%+469.76%+319.38%+483.26%+247.84%ELABPMGC+0.93%+4.85%+3.85%-50.12%-99.73%HCWBHCW Biologics-12.00%-15.20%-49.87%-64.76%-84.70%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXNAddex Therapeutics2.7131 of 5 stars3.54.00.00.02.20.80.6AIMDAinos0.9628 of 5 stars0.04.00.00.01.61.70.6ELABPMGC0.2663 of 5 stars0.02.00.00.01.90.00.6HCWBHCW Biologics3.3284 of 5 stars3.55.00.00.02.03.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 3.00Buy$30.00218.30% UpsideAIMDAinos 0.00N/AN/AN/AELABPMGC 0.00N/AN/AN/AHCWBHCW Biologics 3.00Buy$35.00833.33% UpsideCurrent Analyst Ratings BreakdownLatest ELAB, ADXN, HCWB, and AIMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025HCWBHCW BiologicsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$120.00 ➝ $35.00(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$460K21.72N/AN/A$10.37 per share0.91AIMDAinos$20K559.37N/AN/A$5.51 per share0.48ELABPMGC$1.71M1.88N/AN/A$11.53 per share0.20HCWBHCW Biologics$2.57M2.10N/AN/A($6.08) per share-0.62Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics$8.02M-$0.34N/A∞N/A3,584.49%-54.27%-49.15%9/1/2025 (Estimated)AIMDAinos-$14.86M-$1.29N/A∞N/AN/A-88.07%-48.60%8/4/2025 (Estimated)ELABPMGC-$6.25M-$433.87N/A∞N/AN/A-77.80%-59.17%8/13/2025 (Estimated)HCWBHCW Biologics-$30.02M-$23.25N/A∞N/A-1,712.94%N/A-90.09%8/13/2025 (Estimated)Latest ELAB, ADXN, HCWB, and AIMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HCWBHCW BiologicsN/A-$0.05N/A-$0.05N/AN/A5/14/2025Q1 2025ELABPMGCN/A-$2.90N/A-$2.95N/AN/A5/12/2025Q1 2025AIMDAinosN/A-$0.21N/A-$0.21N/A$0.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AAIMDAinosN/AN/AN/AN/AN/AELABPMGCN/AN/AN/AN/AN/AHCWBHCW BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A3.023.02AIMDAinos0.842.001.91ELABPMGCN/A8.978.97HCWBHCW BiologicsN/A0.070.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%AIMDAinosN/AELABPMGC22.22%HCWBHCW Biologics2.96%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%AIMDAinos10.39%ELABPMGC0.60%HCWBHCW Biologics42.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.06 million901,000Not OptionableAIMDAinos404.19 million3.76 millionNot OptionableELABPMGC181.38 million1.37 millionN/AHCWBHCW Biologics401.44 million825,000Not OptionableELAB, ADXN, HCWB, and AIMD HeadlinesRecent News About These CompaniesHCW Biologics Completes Warrant Exercise with ArmisticeJuly 1 at 9:13 AM | tipranks.comHCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid TumorsJune 27, 2025 | globenewswire.comHCW Biologics Inc.: HCW Biologics Regains Compliance with Nasdaq Capital Market RequirementsJune 26, 2025 | finanznachrichten.deHCW Biologics Inc. Regains Compliance with Nasdaq Listing RequirementsJune 26, 2025 | quiverquant.comQHCW Biologics Regains Nasdaq Compliance as of June 2025June 26, 2025 | tipranks.comHCW Biologics Regains Compliance with Nasdaq Capital Market RequirementsJune 26, 2025 | globenewswire.comHCW Biologics (NASDAQ:HCWB) Raised to "Hold" at Wall Street ZenJune 23, 2025 | americanbankingnews.comHCW Biologics and WY Biotech Finalize Licensing Agreement for HCW11-006, Marking Strategic Development PartnershipJune 6, 2025 | nasdaq.comHCW Biologics Meets Nasdaq Listing Requirements in May 2025June 5, 2025 | tipranks.comHCW Biologics Sinks on Alliance with WY BiotechJune 4, 2025 | baystreet.caHCW Biologics Secures Licensing Agreement with WY BiotechJune 4, 2025 | msn.comHCW Biologics Completes Deliverable and Solidifies License Agreement with WY BiotechJune 4, 2025 | globenewswire.comHCW Biologics Inc.: HCW Biologics Reports First Quarter 2025 Business Highlights and Financial ResultsMay 16, 2025 | finanznachrichten.deHCW Biologics clings on with $5M lifeline to fund phase 1 alopecia trialMay 16, 2025 | fiercebiotech.comFHCW Biologics presents novel CAR-T cell enhancerMay 15, 2025 | uk.investing.comHCW Biologics Inc. Unveils Innovative HCW9206 Fusion Protein at AAI 2025, Promising Enhanced CAR-T Therapy Efficacy and Cost ReductionMay 15, 2025 | nasdaq.comHCW Biologics Reports Positive Results For HCW9206 And Opens Commercial Partnership TalksMay 15, 2025 | nasdaq.comHCW Biologics, Inc.May 15, 2025 | cnn.comHCW Biologics Reports First Quarter 2025 Business Highlights and Financial ResultsMay 15, 2025 | finance.yahoo.comHCW Biologics Inc. Reports Q1 2025 Financial Results and $5 Million Equity Offering CompletionMay 15, 2025 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELAB, ADXN, HCWB, and AIMD Company DescriptionsAddex Therapeutics NASDAQ:ADXN$9.43 +0.02 (+0.16%) Closing price 03:16 PM EasternExtended Trading$9.32 -0.10 (-1.06%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Ainos NASDAQ:AIMD$2.67 -0.16 (-5.65%) As of 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.PMGC NASDAQ:ELAB$2.33 +0.17 (+7.87%) Closing price 04:00 PM EasternExtended Trading$2.33 0.00 (0.00%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.HCW Biologics NASDAQ:HCWB$3.75 -0.21 (-5.30%) Closing price 04:00 PM EasternExtended Trading$3.58 -0.17 (-4.53%) As of 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 2 Reasons to Buy Trade Desk Stock Now and 1 Warning Sign Toast Stock: A Fast-Growing Mid-Cap Eyeing Further Upside Breakout Alert: Disney Stock Hits Multi-Year High 2 Under the Radar Space & Defense Stocks With Huge Potential Palantir’s $100M Nuclear OS Pact Boosts Bullish Case Forget IBM: Accenture’s AI Momentum Is Your Next Buy Joby Stock Soars as Piloted Flights in Dubai Signal a New Era Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
